GH001
Treatment-Resistant Depression (TRD)
Key Facts
About GH Research
GH Research is pioneering a new class of psychiatric treatments based on its proprietary mebufotenin (5-MeO-DMT) platform, targeting difficult-to-treat depression subtypes. Early clinical data from its lead inhaled candidate, GH001, show promising remission rates and rapid onset of action within hours. With a cleared regulatory path and a growing intellectual property portfolio, the company is advancing multiple formulations toward late-stage development in major depressive disorders.
View full company profileAbout GH Research
GH Research is pioneering a new class of psychiatric treatments based on its proprietary mebufotenin (5-MeO-DMT) platform, targeting difficult-to-treat depression subtypes. Early clinical data from its lead inhaled candidate, GH001, show promising remission rates and rapid onset of action within hours. With a cleared regulatory path and a growing intellectual property portfolio, the company is advancing multiple formulations toward late-stage development in major depressive disorders.
View full company profileAbout GH Research
GH Research is pioneering a new class of psychiatric treatments based on its proprietary mebufotenin (5-MeO-DMT) platform, targeting difficult-to-treat depression subtypes. Early clinical data from its lead inhaled candidate, GH001, show promising remission rates and rapid onset of action within hours. With a cleared regulatory path and a growing intellectual property portfolio, the company is advancing multiple formulations toward late-stage development in major depressive disorders.
View full company profileAbout GH Research
GH Research is pioneering a new class of psychiatric treatments based on its proprietary mebufotenin (5-MeO-DMT) platform, targeting difficult-to-treat depression subtypes. Early clinical data from its lead inhaled candidate, GH001, show promising remission rates and rapid onset of action within hours. With a cleared regulatory path and a growing intellectual property portfolio, the company is advancing multiple formulations toward late-stage development in major depressive disorders.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SPN-820/821 | Supernus Pharmaceuticals | Phase 2 |
| BHV-2100 (mGluR2/3 NAM) | Biohaven | Phase 1 |
| PCN-101 (R-ketamine) | atai Life Sciences | Phase 2 |
| VLS-01 (DMT) | atai Life Sciences | Phase 1 |
| Salvianolic Acid B | atai Life Sciences | Preclinical |
| BMB-101 | Bright Minds Biosciences | Phase 2 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 1/2 |
| CYC-126 | Cyclerion Therapeutics | Phase 2 |